241 related articles for article (PubMed ID: 31213765)
1. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
2. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
Salman S; Sy SK; Ilett KF; Page-Sharp M; Paech MJ
Eur J Clin Pharmacol; 2011 Sep; 67(9):899-908. PubMed ID: 21394525
[TBL] [Abstract][Full Text] [Related]
9. Rifampicin markedly decreases the exposure to oral and intravenous tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Neuvonen M; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2013 Jun; 69(6):1293-301. PubMed ID: 23242004
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
11. Development of a linear dual column HPLC-MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid.
Yu H; Hong S; Jeong CH; Bae JW; Lee S
Arch Pharm Res; 2018 Mar; 41(3):288-298. PubMed ID: 29196917
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
Arafa MH; Atteia HH
Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
[TBL] [Abstract][Full Text] [Related]
14. Development of a column-switching LC-MS/MS method of tramadol and its metabolites in hair and application to a pharmacogenetic study.
Yu H; Choi M; Jang JH; Park B; Seo YH; Jeong CH; Bae JW; Lee S
Arch Pharm Res; 2018 May; 41(5):554-563. PubMed ID: 29524157
[TBL] [Abstract][Full Text] [Related]
15. Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration.
Porażka J; Szałek E; Połom W; Czajkowski M; Grabowski T; Matuszewski M; Grześkowiak E
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):579-584. PubMed ID: 30778911
[TBL] [Abstract][Full Text] [Related]
16. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
Allegaert K; Holford N; Anderson BJ; Holford S; Stuber F; Rochette A; Trocóniz IF; Beier H; de Hoon JN; Pedersen RS; Stamer U
Clin Pharmacokinet; 2015 Feb; 54(2):167-78. PubMed ID: 25258277
[TBL] [Abstract][Full Text] [Related]
17. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and
Jeong HC; Bae SH; Bae JW; Lee S; Kim A; Jang Y; Shin KH
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31744222
[TBL] [Abstract][Full Text] [Related]
19. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.
Allegaert K; Anderson BJ; Verbesselt R; Debeer A; de Hoon J; Devlieger H; Van Den Anker JN; Tibboel D
Br J Anaesth; 2005 Aug; 95(2):231-9. PubMed ID: 15951326
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
